2017-10-30 |
1 |
|
formulation of Combigan®. The listed patents are U.S. Patent Nos.
7,030,149, 7,320,976, 7,642,258, 8,133,890…infringed
U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not
…latest of the expiration dates of U.S.
Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258.
…that the claims of the ’149 patent, ’258 patent, ’976
patent, and ’425 patent are invalid and/or will not… infringement of United States Patent No. 9,770,453 (the
“’453 patent”) under 35 U.S.C. § 271(e)(2) and |
External link to document |
2018-05-22 |
112 |
|
the first patent from which issued in 2006,
U.S. Patent No. 7,030,149 (the “’149 patent”). (Id. ¶¶…the “’801 patent”), and 9,907,802 (the “’802 patent). These patents all stem
from a patent application… ’149 patent, the ’425 patent, and a third patent from the first
litigation, the ’976 patent. 6 (Id…other patents, U.S. Patent Nos. 8,133,890 (the “’890 patent”) and 8,354,409 (the
“’409 patent”) that…Allergan Patent Family
beginning with the first patent of this family, the ’149 patent. The inequitable |
External link to document |
2018-07-26 |
166 |
Redacted Document |
149 patent U.S. Patent No. 7,030,149 (Ex. 5)
°976 patent U.S. Patent No. 7,320,976 (Ex. 6)
°258 patent U.S…methods of
treatment. (32); see U.S. Pat. Nos. 7,030,149, 7,323,463, 8,133,890, 8,354,409, 8,748,425,
9,770,453…Apr. 13, 2012)
°453 patent U.S. Patent No. 9,770,453 (Ex. 1)
°801 patent U.S. Patent No. 9,907,801 (Ex.…Ex. 2)
°802 patent U.S. Patent No. 9,907,802 (Ex. 3)
°463 patent USS. Patent No. 7,323,463 (Ex. 4)
°149… U.S. Patent No. 7,642,258 (Ex. 7)
°409 patent U.S. Patent No. 8,354,409 (Ex. 8)
°890 patent U.S. Patent |
External link to document |
2018-08-02 |
173 |
Opinion |
District of Texas, asserting related patents U.S. Patent
Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,…asserts three patents: U.S. Patent Nos. 9,770,453 (“the ’453 patent”);
9,907,801 (“the ’801 patent”); and 9,907,802…complaint asserts three patents: the ’453 patent, the ’801 patent, and the ’802 patent,
Am. Compl. 11 1, ECF…PUBLICATION
B. Patent prosecution
Defendants claim that during the l6-year prosecution of` this patent family…claim that during prosecution of the ’802 patent (one of the patents in
suit), Allergan disclosed some of |
External link to document |
2017-12-18 |
18 |
|
formulation of Combigan®. The listed patents are U.S. Patent Nos. 7,030,149,
7,320,976, 7,642,258, 8,133,890…infringed U.S. Patent
Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …of U.S.
Pat. Nos. 7,030,149 (“the ’149 patent”) and 7,320,976 (“the ’976 patent”) on December 30,
…latest of the expiration dates of U.S. Patent Nos.
7,030,149, 7,320,976, 7,323,463, and 7,642,258.
… No. 91-087 infringed claim 4
of U.S. Patent No. 7,030,149, claim 1 of U.S. Pat. No. 7,320,976, claims |
External link to document |
2019-08-29 |
195 |
|
drug Combigan® infringes U.S. Patent
Nos. 9,770,453 (“the ’453 patent”), 9,907,801 (“the ’801 pa-
tent… of the patent claim. “It is a ‘bedrock principle’ of
patent law that ‘the claims of a patent define the…tent”), and 9,907,802 (“the ’802 patent”) (collectively, “the
Patents-in-Suit”) owned by Allergan. The …Because the Patents-in-Suit share a common spec-
ification, we cite to only the ’453 patent for ease of… of the ’453 patent
recites both a representative efficacy “wherein” clause, ’453
patent col. 9 l. 20– |
External link to document |
2018-01-11 |
29 |
|
of U.S.
Pat. Nos. 7,030,149 (“the ’149 patent”) and 7,320,976 (“the ’976 patent”) on December 30,
2016… the ’149 patent covers Combigan®. Allergan admits the
’149 patent is in the same patent family as …of the ’463 patent are invalid, but in that same opinion, found
claim 4 of the ’149 patent not invalid…the assignee of the ’453 patent and that Defendants
infringe the ’453 patent. Defendants deny that they…of the ’453 patent.
ANSWER: Allergan admits it is the assignee of the ’453 patent and that Defendants |
External link to document |